These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35596539)

  • 41. Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
    Ohue Y; Kurose K; Nozawa R; Isobe M; Nishio Y; Tanaka T; Doki Y; Hori T; Fukuoka J; Oka M; Nakayama E
    Cancer Immunol Res; 2016 Dec; 4(12):1049-1060. PubMed ID: 27799141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
    Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
    Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
    Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
    Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
    Liu T; Greenberg M; Wentland C; Sepe B; Bowe S; Diercks G; Huynh T; Mino-Kenudson M; Schlegel R; Kodack D; Benes C; Engelman J; Hartnick C
    Int J Pediatr Otorhinolaryngol; 2017 Apr; 95():133-138. PubMed ID: 28576522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
    Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
    PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PD-L1 Expression and CD8
    Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
    Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
    Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
    Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
    Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
    Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
    Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
    Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
    Front Immunol; 2021; 12():680973. PubMed ID: 34122444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
    Lippens L; Van Bockstal M; De Jaeghere EA; Tummers P; Makar A; De Geyter S; Van de Vijver K; Hendrix A; Vandecasteele K; Denys H
    Int J Cancer; 2020 Jul; 147(2):554-564. PubMed ID: 32017078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.
    Lu BY; Gupta R; Aguirre-Ducler A; Gianino N; Wyatt H; Ribeiro M; Chiang VL; Contessa JN; Adeniran AJ; Jilaveanu LB; Kluger HM; Schalper KA; Goldberg SB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34670827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.